Clinical Trials for BioInvent International

Explore 6 clinical trials worldwide

Showing 1-6 of 6 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: BioInvent International

Clinical Trials (6)

NCT06784648
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
PHASE1/PHASE2Recruiting
35 participants
Started: Dec 11, 2024 · Completed: Jun 30, 2031
10 conditions2 sponsors9 locations
NCT06205706
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
PHASE1/PHASE2Active, not recruiting
35 participants
Started: Dec 4, 2023 · Completed: Nov 7, 2028
3 conditions2 sponsors8 locations
NCT04725331
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
PHASE1/PHASE2Recruiting
48 participants
Started: Feb 25, 2021 · Completed: Apr 30, 2025
6 conditions3 sponsors5 locations
NCT04752826
BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
PHASE1/PHASE2Recruiting
176 participants
Started: Jan 25, 2021 · Completed: Jan 15, 2028
4 conditions2 sponsors19 locations
NCT04219254
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)
PHASE1/PHASE2Recruiting
197 participants
Started: Jun 29, 2020 · Completed: Nov 30, 2027
1 condition2 sponsors7 locations
NCT03571568
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
PHASE1/PHASE2Recruiting
140 participants
Started: May 16, 2018 · Completed: Sep 30, 2026
1 condition1 sponsor27 locations